Osborne Clarke advises Lucid Group on £11M investment from LDC

International legal practice Osborne Clarke has advised medical education agency, Lucid Group Communications on an £11M investment from LDC, who have taken a minority stake in the business. This investment will help Lucid to continue investing in the infrastructure of the business, expanding its international presence and its digital and creative capabilities.

Founded in 2007, Lucid leads the way in medical education programmes which change the behaviour of healthcare professionals’ and lead to improved patient outcomes. With expertise in therapeutic areas such as oncology, immunology, diabetes, cardiology, neurology and rare diseases, Lucid is recognised as a leader in medical education. Its innovative work has led to consistent industry recognition, including winning Medical Education Consultancy of the Year at the Communique Awards three years running. The company has offices in Beaconsfield, London and New York. Its clients include many of the world’s largest pharmaceutical companies.

Dennis O’Brien, CEO of Lucid commented “We are excited to have entered into this new partnership with LDC as we continue to build an industry leading medical education business. Osborne Clarke have been an invaluable partner throughout our journey. They provided us with pragmatic commercial advice with an amazing service ethic. The entire team were impressive and we thoroughly enjoyed working with them”.

Lucid is a longstanding and valued client of Osborne Clarke. The Corporate team who advised on the transaction was led by Partner Greg Leyshon, Associate Director Mark Saunders, Senior Associate Rebekah Winsor and Associate Alice Wright. Advice on banking was provided by Partner Hugh Jones and Legal Director Rebecca Scott.